Population Pharmacokinetics and Safety of Oral Tetra-Arsenic Tetra-Sulfide Formula in Pediatric Acute Promyelocytic Leukemia

References

• Lo-CocoF, AvvisatiG, VignettiM, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–121. doi:10.1056/NEJMoa130087423841729
   PubMed Web of Science ®Google Scholar
• BurnettAK, RussellNH, HillsRK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295–1305. doi:10.1016/S1470-2045(15)00193-X26384238
   PubMed Web of Science ®Google Scholar
• IlandHJ, CollinsM, BradstockK. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematol. 2015;2(9):e357–366. doi:10.1016/S2352-3026(15)00115-526685769
   PubMed Web of Science ®Google Scholar
• KutnyMA, AlonzoTA, GerbingRB, et al. Arsenic trioxide consolidation allows anthracycline dose reduction for pediatric patients with acute promyelocytic leukemia: report from the children’s oncology group phase III historically controlled trial AAML0631. J Clin Oncol. 2017;35(26):3021–3029. doi:10.1200/JCO.2016.71.618328767288
   PubMed Web of Science ®Google Scholar
• KutnyMA, GregoryJ, FeusnerJH. Treatment of paediatric APL: how does the therapeutic approach differ from adults? Best Pract Res Clin Haematol. 2014;27(1):69–78. doi:10.1016/j.beha.2014.04.00724907019
   PubMed Web of Science ®Google Scholar
• AblaO, KutnyMA, TestiAM, et al. Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel. Br J Haematol. 2016;175(4):588–601. doi:10.1111/bjh.1431327651168
   PubMed Web of Science ®Google Scholar
• ZhangL, ZouY, ChenY, et al. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial. Bmc Cancer. 2018;18(1):374. doi:10.1186/s12885-018-4280-229615003
   PubMed Web of Science ®Google Scholar
• ZhuHH, HuJ, Lo-CocoFet al.The simpler the better: oral arsenic for acute promyelocytic leukemia. Blood. 2019;134(7):597–605. doi:10.1182/blood.201900076031113776
   PubMed Web of Science ®Google Scholar
• ZhuHH, WuDP, JinJ, et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol. 2013;31(33):4215–4221. doi:10.1200/JCO.2013.48.831224127444
   PubMed Web of Science ®Google Scholar
• ZhuHH, WuDP, JinJ, et al. Long-term survival of acute promyelocytic leukaemia patients treated with arsenic and retinoic acid. Br J Haematol. 2016;174(5):820–822. doi:10.1111/bjh.1380927545413
   PubMed Web of Science ®Google Scholar
• ZhuHH, Wu DP, Du X, et al. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. Lancet Oncol. 2018;19(7):871–879. doi:10.1016/S1470-2045(18)30295-X29884593
   PubMed Web of Science ®Google Scholar
• ZhuHH, LiuYR, JiaJS,  et al.  Oral arsenic and all-trans retinoic acid for high-risk acute promyelocytic leukemia. Blood. 2018;131(26):2987–2989. doi:10.1182/blood-2018-02-83405129728404
   PubMed Web of Science ®Google Scholar
• ZhuHH, HuJ, GuXF. Arsenic as traditional Chinese medicine provides new hope for overcoming high treatment costs of acute promyelocytic leukemia. J Global Oncol. 2016;2(6):442–443. doi:10.1200/JGO.2016.005405
   Google Scholar
• Chinese Society of Hematology, Chinese Medical Association, Chinese Medical Doctor Association. Chinese guidelines for diagnosis and treatment of acute promyelocytic leukemia (2018). Chin J Hematol. 2018;39(3):179–183. doi:10.3760/cma.j.issn.0253-2727.2018.03.002
   Google Scholar
• YangMH, WanWQ, LuoJS, et al. Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: interim results of the SCCLG-APL clinical study. Am J Hematol. 2018;93(12):1467–1473. doi:10.1002/ajh.2527130160789
   PubMed Web of Science ®Google Scholar
• ZhaoW, HillH, Le GuellecC, et al. Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age. Antimicrob Agents Chemother. 2014;58(11):6572–6580. doi:10.1128/AAC.03568-1425155587
   PubMed Web of Science ®Google Scholar
• HookerAC, StaatzCE, KarlssonMO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007;24(12):2187–2197. doi:10.1007/s11095-007-9361-x17612795
   PubMed Web of Science ®Google Scholar
• LindbomL, RibbingJ, JonssonEN. Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75(2):85–94. doi:10.1016/j.cmpb.2003.11.00315212851
   PubMed Web of Science ®Google Scholar
• BrendelK, CometsE, LaffontC, et al. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006;23(9):2036–2049. doi:10.1007/s11095-006-9067-516906454
   PubMed Web of Science ®Google Scholar
• BergstrandM, HookerAC, WallinJE, et al. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143–151. doi:10.1208/s12248-011-9255-z21302010
   PubMed Web of Science ®Google Scholar
• CometsE, BrendelK, MentréF. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed. 2008;90(2):154–166. doi:10.1016/j.cmpb.2007.12.00218215437
   PubMed Web of Science ®Google Scholar
• SunF, ChenNN, ChengYB. Compound realgar and natural indigo tablets in treatment of acute promyelocytic leukemia: a summary of experience in 204 cases. Zhong Xi Yi Jie He Xue Bao. 2008;6(6):639–642. doi:10.3736/jcim2008061818559245
   PubMedGoogle Scholar
• The cooperation group of phase II: clinical trial of compound Huangdai tablet, Qian LS, Zhao YZ. phase II clinical trial of compound Huangdai tablet in newly diagnosed acute promyelocytic leukemia. Chin J Hematol. 2006;27(12):801–804. doi:10.3760/cma.j.issn.0253-2727.2006.12.003
   Google Scholar